Veru (NASDAQ:VERU) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Veru (NASDAQ:VERU) in a report issued on Thursday morning,Benzinga reports. They currently have a $3.00 price objective on the stock.

Separately, Oppenheimer reissued an “outperform” rating and issued a $5.00 target price on shares of Veru in a report on Tuesday, November 5th.

Veru Trading Up 13.1 %

NASDAQ:VERU opened at $0.74 on Thursday. Veru has a 12-month low of $0.36 and a 12-month high of $1.92. The firm has a market cap of $107.96 million, a PE ratio of -1.54 and a beta of -0.53. The stock has a fifty day moving average price of $0.70 and a 200 day moving average price of $0.80.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. Equities analysts forecast that Veru will post -0.3 EPS for the current year.

Institutional Trading of Veru

Large investors have recently made changes to their positions in the company. Zacks Investment Management acquired a new position in Veru during the third quarter worth approximately $25,000. Gladstone Institutional Advisory LLC grew its position in shares of Veru by 34.2% during the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock worth $44,000 after acquiring an additional 14,500 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Veru by 185.9% during the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after acquiring an additional 42,997 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Veru by 142.8% in the 3rd quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock valued at $74,000 after acquiring an additional 56,736 shares during the period. Finally, Rhumbline Advisers raised its position in Veru by 3,994.8% in the 2nd quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock valued at $96,000 after purchasing an additional 110,857 shares during the last quarter. 47.16% of the stock is owned by institutional investors and hedge funds.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.